vs
Side-by-side financial comparison of Citius Pharmaceuticals, Inc. (CTXR) and ELBIT SYSTEMS LTD (ESLT). Click either name above to swap in a different company.
ELBIT SYSTEMS LTD is the larger business by last-quarter revenue ($5.8M vs $3.9M, roughly 1.5× Citius Pharmaceuticals, Inc.). ELBIT SYSTEMS LTD runs the higher net margin — 6.3% vs -238.2%, a 244.5% gap on every dollar of revenue.
Citius Pharmaceuticals, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing innovative prescription therapies addressing unmet medical needs across critical care, oncology, anti-infective treatment, and supportive care segments, primarily serving the U.S. healthcare market.
Elbit Systems Ltd. is an Israel-based international military technology company and defense contractor. Founded in 1966 by Elron, Elbit Systems is the primary provider of the Israeli military's land-based equipment and unmanned aerial vehicles. It is an important company within the defense industry of Israel.
CTXR vs ESLT — Head-to-Head
Income Statement — Q1 FY2026 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $3.9M | $5.8M |
| Net Profit | $-9.4M | $367.1K |
| Gross Margin | 80.0% | 24.3% |
| Operating Margin | -228.7% | 8.3% |
| Net Margin | -238.2% | 6.3% |
| Revenue YoY | — | — |
| Net Profit YoY | 8.6% | — |
| EPS (diluted) | $-0.38 | $7.85 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $7.7M | $265.4K |
| Total DebtLower is stronger | — | $90.7K |
| Stockholders' EquityBook value | $80.0M | $3.3M |
| Total Assets | $140.4M | $11.0M |
| Debt / EquityLower = less leverage | — | 0.03× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $7.7M | — | ||
| Q3 25 | — | $265.4K |
| Q4 25 | — | — | ||
| Q3 25 | — | $90.7K |
| Q4 25 | $80.0M | — | ||
| Q3 25 | — | $3.3M |
| Q4 25 | $140.4M | — | ||
| Q3 25 | — | $11.0M |
| Q4 25 | — | — | ||
| Q3 25 | — | 0.03× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-13.0M | $534.6K |
| Free Cash FlowOCF − Capex | — | $319.6K |
| FCF MarginFCF / Revenue | — | 5.5% |
| Capex IntensityCapex / Revenue | — | 3.7% |
| Cash ConversionOCF / Net Profit | — | 1.46× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-13.0M | — | ||
| Q3 25 | — | $534.6K |
| Q4 25 | — | — | ||
| Q3 25 | — | $319.6K |
| Q4 25 | — | — | ||
| Q3 25 | — | 5.5% |
| Q4 25 | — | — | ||
| Q3 25 | — | 3.7% |
| Q4 25 | — | — | ||
| Q3 25 | — | 1.46× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
